2,6-二甲基-5-碘-4(3H-)-嘧啶酮 | 83410-37-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2,6-二甲基-5-碘-4(3H-)-嘧啶酮
• 英文名称: 5-iodo-2,6-dimethylpyrimidin-4-ol
• 英文别名: 5-Iodo-2,6-dimethylpyrimidin-4-ol；5-iodo-2,4-dimethyl-1H-pyrimidin-6-one
• CAS: 83410-37-1
• 化学式: C₆H₇IN₂O
• 分子量: 250.039
• InChiKey: LLRCHCURQABDLS-UHFFFAOYSA-N

物化性质

• 熔点：
  196-199 °C
• 沸点：
  254.9±43.0 °C(Predicted)
• 密度：
  2.03±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  2,6-二甲基-5-碘-4(3H-)-嘧啶酮 在 四(三苯基膦)钯 、 碳酸氢钠 、 lithium chloride 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 甲苯 、 正丁醇 为溶剂， 反应 96.0h， 生成 4-(4-bromobenzylamino)-2,6-dimethyl-5-(1-ethoxyvinyl)pyrimidine
  参考文献：
  名称：

  Metabolites of the Angiotensin II Antagonist Tasosartan:  The Importance of a Second Acidic Group

  摘要：

  Described in this paper is the synthesis and pharmacological activity of five metabolites of the angiotensin II antagonist tasosartan (1). Of particular interest is the effect of the additional acidic group of the enol metabolite (8) on activity. As suggested by the structural-activity relationship of other angiotensin II antagonist series, a second acidic group can improve receptor binding activity but decrease in vivo activity after oral dosing. The metabolic introduction of a second acidic group in tasosartan bypasses this problem and contributes to the excellent profile of the compound. A molecular modeling study provides a rationale for the role of the enol group of 8 in AT(1) receptor binding.

  DOI：

  10.1021/jm970690q
• 作为产物：
  描述：

  2,4-二甲基-6-羟基嘧啶 在 sodium hydroxide 、 碘 作用下， 以 水 为溶剂， 以49%的产率得到2,6-二甲基-5-碘-4(3H-)-嘧啶酮
  参考文献：
  名称：

  通过钯催化炔基嘧啶与芳基碘化物的环化反应，合成新型5,6-取代的呋喃并[2,3- d ]嘧啶

  摘要：

  描述了一种合成5,6-二取代的呋喃并[2,3- d ]嘧啶衍生物的灵活方法。关键步骤是用各种芳基碘化物对炔基嘧啶进行钯催化的芳基环化反应，标题化合物的收率为36-75％。

  DOI：

  10.1016/j.tet.2006.12.077

文献信息

• Compounds for treating spinal muscular atrophy
  申请人：PTC Therapeutics Inc.

  公开号：US09617268B2

  公开（公告）日：2017-04-11

  Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.

  本文提供了用于治疗脊髓性肌萎缩症的化合物、其组合物和使用方法。在一个具体实施例中，本文提供了一种形式的化合物，可用于调节从SMN2基因转录的mRNA中SMN2的外显子7的包含。在另一个具体实施例中，本文提供了一种形式的化合物，可用于调节从SMN1基因转录的mRNA中SMN1的外显子7的包含。在另一个实施例中，本文提供了一种形式的化合物，可用于调节从SMN1和SMN2基因分别转录的mRNA中SMN1和SMN2的外显子7的包含。
• CYCLOPROPANE COMPOUND
  申请人：Terauchi Taro

  公开号：US20120095031A1

  公开（公告）日：2012-04-19

  A cyclopropane compound represented by the following formula (A) or a pharmaceutically acceptable salt thereof has orexin receptor antagonism, and therefore has a potencial of usefulness for the treatment of sleep disorder for which orexin receptor antagonism is effective, for example, insomnia: wherein Q represents —CH— or a nitrogen atom, R 1a and R 1b each independently represent a C 1-6 alkyl group and the like, R 1c represents a hydrogen atom and the like, R 2a , R 2b , R 2c and R 2d each independently represent a hydrogen atom, a halogen atom, a C 1-6 alkyl group and the like, R 3a , R 3b and R 3c each independently represent a hydrogen atom, a halogen atom and the like, and R 3d represents a hydrogen atom and the like.

  一种环丙烷化合物，其化学式如下（A），或其药学上可接受的盐具有促进俄雷昔康受体拮抗作用，因此具有治疗俄雷昔康受体拮抗有效的睡眠障碍的潜力，例如失眠：其中Q代表—CH—或氮原子，R1a和R1b分别独立表示C1-6烷基基团等，R1c表示氢原子等，R2a，R2b，R2c和R2d分别独立表示氢原子，卤素原子，C1-6烷基基团等，R3a，R3b和R3c分别独立表示氢原子，卤素原子等，R3d表示氢原子等。
• Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
  申请人：Beard D. Charles

  公开号：US20060183758A1

  公开（公告）日：2006-08-17

  Methods of synthesis of intermediates that are useful as bioisosteres of the indole, benzofuran and benzothiophene scaffold are disclosed.

  公开了一种合成中间体的方法，这些中间体可作为吲哚、苯并呋喃和苯并噻吩骨架的生物同位素。
• [EN] EZH2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'EZH2 ET LEURS UTILISATIONS
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2016073956A1

  公开（公告）日：2016-05-12

  The present disclosure provides compounds of any one of Formulae (I) and (II). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. Further provided in the present disclosure are methods of identifying EZH1and/or EZH2 inhibitors.

  本公开提供了任一式（I）和（II）中的化合物。本文描述的化合物是组蛋白甲基转移酶抑制剂（例如增强子齿同源蛋白1（EZH1）和增强子齿同源蛋白2（EZH2）），可用于治疗和/或预防广泛范围的疾病（例如增生性疾病）。本公开还提供了包括或使用本文描述的化合物的药物组合物、试剂盒、方法和用途。本公开还提供了识别EZH1和/或EZH2抑制剂的方法。
• Studies on pyrimidine derivatives. XXVIII. Synthesis of pyridopyrimidine derivatives by cross-coupling of halopyrimidines with olefins and acetylenes.
  作者：TAKAO SAKAMOTO、YOSHINORI KONDO、HIROSHI YAMANAKA

  DOI：10.1248/cpb.30.2410

  日期：——

  Three kinds of pyridopyrimidines were synthesized from appropriate pyrimidine derivatives. Cross-coupling of 4-amino-5-iodopyrimidines with α, β-unsaturated carboxylic esters followed by ring-closure afforded pyrido [2, 3-d] pyrimidines. Ammonolysis of 4-ethoxycarbonyl-5-phenylethynyl-and 5-ethoxycarbonyl-4-phenyl-ethynyl-pyrimidines which were obtained by cross-coupling of the corresponding halopyrimidines with phenylacetylene, gave pyrido [3, 4-d]-and pyrido [4, 3-d]-pyrimidines, respectively.

  由适当的嘧啶衍生物合成了三种吡啶嘧啶。4-amino-5-iodopyrimidines 与 α, β-unsaturated carboxylic esters 发生交叉偶联，然后进行闭环反应，得到吡啶并[2, 3-d] 嘧啶。4- 乙氧羰基-5-苯基乙炔基和 5- 乙氧羰基-4-苯基乙炔基嘧啶通过相应的卤代嘧啶与苯乙炔的交叉偶联得到了吡啶并[3，4-d]嘧啶和吡啶并[4，3-d]嘧啶。

表征谱图